Skip to main content
. 2022 Mar 17;36(6):855–865. doi: 10.1111/jdv.18010

Figure 2.

Figure 2

Achievement of absolute PASI thresholds over time. Percentage of patients achieving absolute PASI scores of (a) ≤3, (b) ≤1, (c) or = 0 over time for patients receiving risankizumab or ustekinumab (NRI). NRI, non‐responder imputation; PASI, Psoriasis Area and Severity Index; RZB, risankizumab; UST, ustekinumab. **P < 0.01; ***P < 0.001 compared to UST. Arrows indicate timing of doses for patients with either 150 mg RZB or weight‐based UST (45/90 mg UST).